U.S. IT Stock News

Tarsus Pharmaceuticals (TARS) has been drawing attention after recent trading swings, with the stock closing at US$59.64 while showing mixed returns over the past month and past 3 months, alongside a positive one year track record. See our latest analysis for Tarsus Pharmaceuticals. The share price has been under pressure in recent months, with a 90 day share price return down 18.32% and year to date share price return down 26.16%. At the same time, the 1 year total shareholder return sits at...

Lumentum Holdings recently raised its fourth-quarter guidance and reported very large year-over-year revenue growth, citing intense AI-driven demand for its cloud networking and optical components, while also executing a US$650.4 million private exchange of convertible notes for equity to reduce debt. At the same time, the company secured a multi-year US$2 billion agreement with Nvidia and is expanding manufacturing capacity, including an indium phosphide fab in North Carolina, highlighting...

Event context and recent stock performance Palvella Therapeutics (PVLA) has drawn fresh attention after recent trading saw the stock close at US$105.25. This move comes alongside a year-to-date gain of 5% and a 1-year total return near 3x. See our latest analysis for Palvella Therapeutics. Recent trading has been choppy, with the share price down 3.15% on the day, 6.52% over the past week and 25.94% over the past quarter. At the same time, the 1 year total shareholder return sits near 3x,...

Why Azenta (AZTA) is on investors’ radar today Azenta (AZTA) continues to draw attention after a mixed stretch of performance that includes a gain over the past month but weaker returns year to date and over the past year. With a market value of about US$1.0b and reported revenue of US$596.5m, the company sits in an interesting spot for investors comparing growth potential, profitability and valuation against other life sciences service providers. See our latest analysis for Azenta. At the...

Some Natera, Inc. ( NASDAQ:NTRA ) shareholders may be a little concerned to see that the Lead Independent Director...

Ryder System (R) is back on investors’ radar after a mix of upbeat analyst commentary, positive earnings surprises, and ongoing capital returns, including steady dividends and buybacks, despite a freight market that remains under pressure. See our latest analysis for Ryder System. The recent optimism around Ryder System has coincided with strong momentum, with a 30 day share price return of 13.3% and a 90 day share price return of 33.7%. The 1 year total shareholder return of 80.4% sits...

Why STERIS Stock Is On Investors’ Radar Today Without a specific news headline driving STERIS (STE) today, investors are refocusing on the company’s fundamentals, including its healthcare focused revenue mix and recent share price moves over the past year. See our latest analysis for STERIS. At a share price of US$210.03, STERIS has experienced softer short-term share price performance, with the 1-day move down 1.09% and the 90-day share price return declining 5.43%, while the 5-year total...

Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease access for an expanding network of authorized treatment centers. This move deepens Cencora’s presence in complex cell and gene therapies, highlighting its role in handling highly specialized, patient-specific treatments that can be operationally challenging for providers. Next, we’ll examine...

In early June 2026, NewAmsterdam Pharma filed a US$37.57 million shelf registration for 1,150,000 ordinary shares tied to its ESOP, while shareholders also approved Deloitte Accountants B.V. as external auditor for the 2026 fiscal year and statutory Dutch reporting. Investor attention has been amplified after prominent investor Stanley Druckenmiller highlighted NewAmsterdam Pharma as a top non‑AI idea, coinciding with high-profile healthcare conference appearances to discuss its late-stage...

Recent performance snapshot and context SL Green Realty (SLG) has been drawing attention after a recent stretch of mixed returns, with the stock up over the past week and past 3 months but down over the past year. See our latest analysis for SL Green Realty. For context, the stock’s recent upswing, including a 27.02% 90 day share price return, contrasts with a 20.35% decline in 1 year total shareholder return. As a result, near term momentum appears to be rebuilding from a weaker longer term...

Glacier Bancorp (GBCI) stock has drawn fresh attention after recent trading left it around $47.12, with mixed short term returns that include gains over the past 3 months but a decline over the past month. See our latest analysis for Glacier Bancorp. At around $47.12, the stock’s recent 3 month share price return of 5.39% contrasts with a 3.42% move down over the past month, while the 1 year total shareholder return of 12.90% sits alongside a modest total shareholder loss over 5 years. This...

Victoria's Secret & Co. ( NYSE:VSXY ) just released its latest quarterly results and things are looking bullish. It was...

Recent performance and what has caught investors’ attention Reinsurance Group of America (RGA) has drawn fresh interest after recent share price moves, with the stock ending the latest session at US$201.21 and sitting slightly down year to date. Short term returns have been mixed, with the stock down about 2% over the past week, down roughly 4% over the past month, and lower by around 3% over the past 3 months, while the 1 year total return is slightly positive. See our latest analysis for...

Zevra Therapeutics recently disclosed that shareholders at its June 4, 2026 annual meeting rejected an amendment to phase out the company’s classified board structure, which would have shifted all directors to one-year terms beginning with the 2027 annual meeting. Around the same time, Zevra moved to strengthen its intellectual property position by asking the U.S. Food and Drug Administration to list a new MIPLYFFA patent in the Orange Book, aiming to extend patent protection to 2041 and...

In recent days, McKesson reported a mixed quarter but reinforced its long‑term plans, while major Wall Street banks reaffirmed positive views on the company’s outlook and multi-year guidance. At the same time, ongoing insider share sales and assessments of the stock as modestly overvalued have sharpened investor focus on how credible its fiscal 2027 ambitions really are. We’ll now examine how analysts’ support for McKesson’s fiscal 2027 guidance could influence the company’s existing...

Helmerich & Payne’s board on June 3, 2026, declared a quarterly cash dividend of US$0.25 per common share, payable on September 1 to shareholders of record as of August 18, alongside reporting a fiscal second-quarter net loss influenced by a non-cash impairment. The company also exceeded its asset divestiture goal with the sale of the Utica Square retail center and renewed a major Caspian Sea offshore operations and maintenance contract through its TURAN joint venture, reinforcing its focus...

The SpaceX IPO hype is not just about one company; it is reshaping attention and capital around space and AI, and that can create both openings and pressure points for other stocks. With a US$75 billion offer for 5% of the company and a US$1.75 trillion valuation tied closely to its xAI ambitions, investors are suddenly rethinking which companies might lose out as money and headlines gravitate toward this new listing. This article highlights 3 stocks exposed to that news, each at risk of...

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported new clinical data for its next-generation cystic fibrosis therapy ALYFTREK in young children. The company also outlined progress on global regulatory submissions for ALYFTREK and TRIKAFTA in pediatric populations. The updates focus on expanding treatment access to children as young as 2 years old and on long term safety findings in older patients. Vertex Pharmaceuticals sits at the center of the cystic fibrosis treatment market, and the latest...

Recent attention on Tuya (TUYA) has been driven by its pivot toward AI integrated software and AI enabled consumer hardware, as investors weigh the potential of its PaaS and AI applications segments. See our latest analysis for Tuya. Despite the buzz around Tuya’s AI focused PaaS and hardware ambitions, the stock has retreated, with the 30 day share price return down 22.18% and the 1 year total shareholder return down 29.02%. This suggests recent enthusiasm has cooled after earlier multi year...

Cousins Properties (CUZ) has been in focus after management expanded its share buyback program to $500 million, secured a long-term Oracle lease at Neuhoff, and raised 2026 FFO guidance on higher leasing assumptions. See our latest analysis for Cousins Properties. The recent buyback expansion and Oracle lease come against a backdrop of stronger momentum, with the share price up 22.0% over 90 days and a 3 year total shareholder return of 53.7%, even though the latest price of $28.32 leaves the...

NGL Energy Partners LP has reported past fourth-quarter 2026 revenue of US$949.51 million and a net loss of US$287.68 million, reversing from profit a year earlier and contributing to a full-year loss on lower annual revenue of US$3.16 billion. Despite this swing into loss, the partnership continued its unit repurchase program through March 2026, retiring about 6.71% of outstanding units for roughly US$49.56 million, which may influence how investors interpret management’s confidence and...

American Electric Power Company (AEP) has just completed a Federal Energy Regulatory Commission approved overhaul of its Ohio Valley Electric Corporation interests, shifting power entitlements and equity stakes within the group. For investors, this regulatory milestone reframes how to think about AEP’s risk profile and capital priorities. See our latest analysis for American Electric Power Company. At a share price of $126.77, AEP has eased 1.8% over the past day but still sits on a 9.5% year...

In its recently reported fiscal 2026 second quarter, Spire Inc. posted adjusted earnings of US$3.76 per share with year-over-year revenue contraction and updated its full-year adjusted earnings guidance to a range below earlier market expectations. Alongside the softer near-term outlook, Spire outlined US$11.20 billion of planned capital investments through fiscal 2035, signaling a significant long-horizon build-out of its regulated infrastructure base. Next, we’ll examine how the lowered...

Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with projected annual earnings growth of 17%. In this fluctuating environment, identifying small-cap stocks that are undervalued and exhibit insider activity can present unique opportunities for investors seeking to capitalize on potential market inefficiencies.